Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis. (2017). SKIN The Journal of Cutaneous Medicine, 1(3.1), s10. https://doi.org/10.25251/skin.1.supp.9